Steven M. Albelda, MD, discusses what he expects the future of chimeric antigen receptor T-cell use in solid tumors to look like.
Steven Albelda, MD
Advertisement
Steven Albelda, MD, is William Maul Measey Professor of Medicine, Member of the Penn Abramson Cancer Center, director of Thoracic Oncology Research Laboratory, and codirector of the Translational Center of Excellence in Lung Cancer, Abramson Cancer Center, University of Pennsylvania.
Articles by Steven Albelda, MD
Steven M. Albelda, MD, discusses the limited successes of CAR T cells in solid tumors.
Steve M. Albelda, MD, discusses the successes and downfalls of chimeric antigen receptor T cells in solid tumor research.
Advertisement
Latest Updated Articles
Research Still Needed on CAR T Cells in Solid TumorsPublished: April 3rd 2022 | Updated:
Discussing the Use of CAR T Cells in Solid TumorsPublished: May 11th 2022 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
